Jeffrey Martini, an officer of Palvella Therapeutics, Inc., filed a Form 144 notice on November 10, 2026, disclosing a proposed sale of 50,000 shares of common stock under Rule 144 of the Securities Act of 1933.
Key Highlights
- Seller: Jeffrey Martini, identified as an officer of Palvella Therapeutics, Inc.
- Shares proposed for sale: 50,000 shares of common stock, with an aggregate market value of $8,704,000.00 as stated in the filing.
- Shares outstanding: 14,618,457 shares of common stock outstanding, according to the filing.
- Source of shares: The shares are to be received upon the exercise of stock options, acquired from the issuer.
- Approximate date of sale: November 10, 2026, through broker Morgan Stanley Smith Barney LLC Executive Financial Services.
- Rule 10b5-1 plan: A written trading plan was adopted on July 13, 2026, according to the filing.
- Prior sales in past 3 months: Nothing to report, per the filing.
Martini's Proposed Option-Backed Share Sale at Palvella Therapeutics
According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Jeffrey Martini, an officer of Palvella Therapeutics, Inc. (NASDAQ:PVLA), intends to sell 50,000 shares of the company's common stock. The filing states the aggregate market value of the proposed sale is $8,704,000.00. The shares are listed on NASDAQ, and the broker named to handle the transaction is Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
The filing indicates the shares originate from the exercise of stock options granted by the issuer. Both the acquisition date and the date of payment are listed as November 10, 2026, with payment described as cash. The remarks section of the filing states: "The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale."
The filing also discloses that Martini adopted a written trading plan under Rule 10b5-1 of the Securities Exchange Act on July 13, 2026. No sales of Palvella Therapeutics securities were reported by Martini in the three months preceding this notice. The total shares of common stock outstanding are reported in the filing as 14,618,457.
What Was Disclosed
Palvella Therapeutics officer Jeffrey Martini filed a Form 144 notice on November 10, 2026, proposing the sale of 50,000 common shares acquired through stock option exercises, with an aggregate market value of $8,704,000.00, executed under a Rule 10b5-1 plan adopted July 13, 2026.




Please wait processing your request...